Literature DB >> 18799475

Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin.

Glen B Banks1, Ariana C Combs, Joel R Chamberlain, Jeffrey S Chamberlain.   

Abstract

Myotendinous strain injury is the most common injury of human skeletal muscles because the majority of muscle forces are transmitted through this region. Although the immediate response to strain injury is well characterized, the chronic response to myotendinous strain injury is less clear. Here we examined the molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a microdystrophin transgene (microdystrophin(DeltaR4-R23)). We found that muscles with myotendinous strain injury had an increased expression of utrophin and alpha7-integrin together with the dramatic restructuring of peripheral myofibrils into concentric rings. The sarcolemma of the microdystrophin(DeltaR4-R23)/mdx gastrocnemius muscles was highly protected from experimental lengthening contractions, better than wild-type muscles. We also found a positive correlation between myotendinous strain injury and ringed fibers in the HSA(LR) (human skeletal actin, long repeat) mouse model of myotonic dystrophy. We suggest that changes in protein expression and the formation of rings are adaptations to myotendinous strain injury that help to prevent muscle necrosis and retain the function of necessary muscles during injury, ageing and disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799475      PMCID: PMC2638580          DOI: 10.1093/hmg/ddn301

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  59 in total

1.  Dystrobrevin and dystrophin: an interaction through coiled-coil motifs.

Authors:  H M Sadoulet-Puccio; M Rajala; L M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

2.  Experimental muscle strain injury. Early functional and structural deficits and the increased risk for reinjury.

Authors:  D C Taylor; J D Dalton; A V Seaber; W E Garrett
Journal:  Am J Sports Med       Date:  1993 Mar-Apr       Impact factor: 6.202

3.  Relationship between muscle fiber types and sizes and muscle architectural properties in the mouse hindlimb.

Authors:  T J Burkholder; B Fingado; S Baron; R L Lieber
Journal:  J Morphol       Date:  1994-08       Impact factor: 1.804

4.  Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy.

Authors:  A E Deconinck; J A Rafael; J A Skinner; S C Brown; A C Potter; L Metzinger; D J Watt; J G Dickson; J M Tinsley; K E Davies
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

5.  [Intramuscular degeneration process in Duchenne muscular dystrophy--investigation by longitudinal MR imaging of the skeletal muscles].

Authors:  T Hasegawa; K Matsumura; T Hashimoto; H Ikehira; H Fukuda; Y Tateno
Journal:  Rinsho Shinkeigaku       Date:  1992-03

6.  Dystrophin deficiency is associated with myotendinous junction defects in prenecrotic and fully regenerated skeletal muscle.

Authors:  D J Law; J G Tidball
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

7.  Site and mechanics of failure in normal and dystrophin-deficient skeletal muscle.

Authors:  D J Law; A Caputo; J G Tidball
Journal:  Muscle Nerve       Date:  1995-02       Impact factor: 3.217

8.  Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle.

Authors:  T S Khurana; S C Watkins; P Chafey; J Chelly; F M Tomé; M Fardeau; J C Kaplan; L M Kunkel
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

9.  Animal models for muscular dystrophy show different patterns of sarcolemmal disruption.

Authors:  V Straub; J A Rafael; J S Chamberlain; K P Campbell
Journal:  J Cell Biol       Date:  1997-10-20       Impact factor: 10.539

10.  Forced expression of dystrophin deletion constructs reveals structure-function correlations.

Authors:  J A Rafael; G A Cox; K Corrado; D Jung; K P Campbell; J S Chamberlain
Journal:  J Cell Biol       Date:  1996-07       Impact factor: 10.539

View more
  18 in total

Review 1.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

Review 2.  The Dystrophin Complex: Structure, Function, and Implications for Therapy.

Authors:  Quan Q Gao; Elizabeth M McNally
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

Review 3.  Cell death, clearance and immunity in the skeletal muscle.

Authors:  C Sciorati; E Rigamonti; A A Manfredi; P Rovere-Querini
Journal:  Cell Death Differ       Date:  2016-02-12       Impact factor: 15.828

4.  Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6.

Authors:  Guy L Odom; Paul Gregorevic; James M Allen; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2010-09-21       Impact factor: 11.454

5.  Truncated dystrophins can influence neuromuscular synapse structure.

Authors:  Glen B Banks; Jeffrey S Chamberlain; Stanley C Froehner
Journal:  Mol Cell Neurosci       Date:  2009-01-08       Impact factor: 4.314

6.  The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins.

Authors:  Glen B Banks; Luke M Judge; James M Allen; Jeffrey S Chamberlain
Journal:  PLoS Genet       Date:  2010-05-20       Impact factor: 5.917

7.  Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting.

Authors:  Kristy Swiderski; Scott A Shaffer; Byron Gallis; Guy L Odom; Andrea L Arnett; J Scott Edgar; Dale M Baum; Annabel Chee; Timur Naim; Paul Gregorevic; Kate T Murphy; James Moody; David R Goodlett; Gordon S Lynch; Jeffrey S Chamberlain
Journal:  Hum Mol Genet       Date:  2014-07-31       Impact factor: 6.150

8.  Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy.

Authors:  Jane T Seto; Niclas E Bengtsson; Jeffrey S Chamberlain
Journal:  Curr Pediatr Rep       Date:  2014-06-01

9.  Myotendinous junction defects and reduced force transmission in mice that lack alpha7 integrin and utrophin.

Authors:  Jennifer V Welser; Jachinta E Rooney; Nicolette C Cohen; Praveen B Gurpur; Cherie A Singer; Rebecca A Evans; Bryan A Haines; Dean J Burkin
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

Review 10.  Emerging strategies for cell and gene therapy of the muscular dystrophies.

Authors:  Lindsey A Muir; Jeffrey S Chamberlain
Journal:  Expert Rev Mol Med       Date:  2009-06-25       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.